X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5090) 5090
Book Chapter (9) 9
Book / eBook (2) 2
Magazine Article (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
Newspaper Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3433) 3433
animals (2489) 2489
bone density conservation agents - pharmacology (2433) 2433
female (2426) 2426
osteoporosis (1912) 1912
bone density conservation agents - therapeutic use (1721) 1721
male (1469) 1469
bone density - drug effects (1192) 1192
pharmacology & pharmacy (1069) 1069
bisphosphonates (956) 956
rats (942) 942
middle aged (934) 934
diphosphonates - pharmacology (928) 928
aged (877) 877
postmenopausal women (873) 873
endocrinology & metabolism (865) 865
osteoporosis - drug therapy (844) 844
bone density conservation agents - administration & dosage (837) 837
mice (822) 822
diphosphonates - therapeutic use (754) 754
alendronate (727) 727
zoledronic acid (717) 717
orthopedics (653) 653
bones (634) 634
bone density conservation agents - adverse effects (580) 580
medicine & public health (575) 575
fractures (570) 570
analysis (560) 560
osteoporosis, postmenopausal - drug therapy (511) 511
bone density (502) 502
bone (493) 493
bone and bones - drug effects (484) 484
research (476) 476
in-vitro (474) 474
bone-mineral density (472) 472
disease models, animal (455) 455
imidazoles - pharmacology (454) 454
density (447) 447
drug therapy (442) 442
rats, sprague-dawley (439) 439
ovariectomy (437) 437
bone remodeling - drug effects (429) 429
treatment outcome (429) 429
health aspects (423) 423
women (414) 414
adult (412) 412
rheumatology (410) 410
cells, cultured (405) 405
oncology (401) 401
osteoclasts - drug effects (386) 386
alendronate - pharmacology (378) 378
bone mineral density (372) 372
risk factors (371) 371
diphosphonates - administration & dosage (368) 368
cell biology (366) 366
osteogenesis - drug effects (366) 366
endocrinology (365) 365
bisphosphonate (362) 362
care and treatment (359) 359
aged, 80 and over (357) 357
osteoblasts - drug effects (346) 346
therapy (346) 346
dose-response relationship, drug (344) 344
prevention (343) 343
mineral density (338) 338
risk (333) 333
postmenopausal osteoporosis (330) 330
differentiation (325) 325
bone and bones - metabolism (321) 321
medicine, research & experimental (320) 320
diphosphonates - adverse effects (319) 319
time factors (319) 319
apoptosis (317) 317
internal medicine (307) 307
expression (304) 304
cancer (301) 301
rats, wistar (287) 287
double-blind (286) 286
dentistry (282) 282
medicine (276) 276
bone resorption (271) 271
stem cells (271) 271
rodents (268) 268
dentistry, oral surgery & medicine (266) 266
osteoporosis - prevention & control (265) 265
denosumab (262) 262
cell differentiation - drug effects (261) 261
bone neoplasms - secondary (258) 258
cell proliferation - drug effects (258) 258
physiological aspects (253) 253
risedronate (252) 252
pharmacology (251) 251
cells (245) 245
research article (241) 241
bone neoplasms - drug therapy (239) 239
calcium (239) 239
vitamin d (239) 239
bone marrow (238) 238
osteoclasts (236) 236
surgery (236) 236
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5014) 5014
Japanese (114) 114
Chinese (22) 22
French (12) 12
Russian (11) 11
Spanish (10) 10
Polish (9) 9
German (6) 6
Italian (3) 3
Croatian (2) 2
Hungarian (2) 2
Portuguese (2) 2
Arabic (1) 1
Danish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
...B ligand, on bone mineral density and fractures in such men. Use of denosumab was associated with increased bone mineral density at all sites and reduction in the incidence of new vertebral fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 5, pp. 412 - 420
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 15, pp. 1417 - 1427
... is an antiresorptive agent commonly used as first-line therapy for osteoporosis. In a trial involving postmenopausal women with prevalent fractures, the risks of vertebral... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 1945-7197, 2011, Volume 96, Issue 4, pp. 972 - 980
Journal Article
Nature medicine, ISSN 1546-170X, 2008, Volume 14, Issue 7, pp. 767 - 772
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 756 - 765
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2014, Volume 54, Issue 2, pp. 168 - 178
...%, and increased lumbar spine bone mineral density by 4–7%. Two subjects developed neutralizing antibodies without discernable effects on pharmacokinetics, pharmacodynamics, or safety... 
CDP7851 | romosozumab | bone mineral density | pharmacodynamics | pharmacokinetics | AMG 785 | sclerostin | Pharmacodynamics | Sclerostin | Bone mineral density | Romosozumab | Pharmacokinetics | PROTEIN | STRENGTH | OSTEOPOROSIS | DENSITY | GENE | PHARMACOLOGY & PHARMACY | SOST | Collagen Type I - blood | Peptides - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Osteoporosis, Postmenopausal - metabolism | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - pharmacology | Peptide Fragments - blood | Aged, 80 and over | Female | Bone Density Conservation Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Lumbar Vertebrae - drug effects | Procollagen - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Antibodies, Monoclonal - administration & dosage | Aged | Viral antibodies | Antibodies | Care and treatment | Dosage and administration | Postmenopausal women | Research | Osteoporosis | Men
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 18, pp. 1714 - 1723
.... 3 Mortality after osteoporotic fracture is higher among men than among women. 2 , 4 Previous studies involving men with osteoporosis have focused on the surrogate outcomes of bone mineral density and bone-turnover markers, 5... 
BONE-DENSITY | MORTALITY | HIP FRACTURE | WOMEN | MEDICINE, GENERAL & INTERNAL | VERTEBRAL FRACTURES | DENOSUMAB | DOUBLE-BLIND | ORAL ALENDRONATE | RISEDRONATE | PREVALENCE | Humans | Middle Aged | Male | Osteoporosis - drug therapy | Risk | Osteoporosis - etiology | Spinal Fractures - prevention & control | Aged, 80 and over | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Testosterone - blood | Diphosphonates - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Imidazoles - adverse effects | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Logistic Models | Imidazoles - pharmacology | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Analysis of Variance | Hypogonadism - complications | Aged | Diphosphonates - pharmacology | Drugs | Dose-response relationship (Biochemistry) | Osteoporosis | Men | Zoledronic acid | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Risk factors | Vertebrae | Intravenous administration | Calcium | Clinical trials | Bone turnover | Hypogonadism | Serum levels | Testosterone | Fractures | Vitamin D | Older people | Bone mineral density | Bone density | Supplementation
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article